Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Melanoma 5Uveal Melanoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Melanoma × fotemustine × Dermatologic × Clear all
NCT00560118 2025-02-14

MGFOT1

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Terminated
12 enrolled
Dermatologic

Melanoma

NCT01359956 2023-04-11

SICOG 0109

National Cancer Institute, Naples

Phase 3 Completed
269 enrolled 12 charts
Dermatologic

Melanoma

NCT01069627 2018-12-06

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Hoffmann-La Roche

Phase 2 Completed
20 enrolled 21 charts
Dermatologic

Melanoma

NCT01983124 2016-01-20

BeyPro1

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Phase 2 Completed
31 enrolled
Dermatologic

Melanoma

NCT01654692 2015-05-13

NIBIT-M1

Italian Network for Tumor Biotherapy

Phase 2 Completed
86 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡